Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Prostate Cancer
Interventions: High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: androgen-deprivation therapy, docetaxel; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2025
U.S. locations: 343
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 243 more

Conditions: Prostate Cancer
Interventions: Oral Triamcinalone; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Cancer
Interventions: Blood draw, Tissue biopsy; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions: laboratory biomarker analysis, quality-of-life assessment, questionnaire administration, cinacalcet hydrochloride; Other · Procedure · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions: Consultation audio recording app; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer, Supportive Care
Interventions: Exercise Training Intervention, Healthy Living Education; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Prostate Carcinoma
Interventions: Community Health Service, Questionnaire Administration; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: High-Risk Prostate Cancer
Interventions: Capivasertib, abiraterone acetate; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: West Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 6 more

Conditions: Prostate Cancer
Interventions: Docetaxel, Radiation Therapy, Casodex and Zoladex (or Lupron); Drug · Radiation
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hormone Refractory Prostate Cancer, Recurrent Prostate Cancer
Interventions: cediranib maleate, dasatinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 5
States / cities: Peoria, Illinois • Springfield, Illinois • Fort Wayne, Indiana + 2 more

Conditions: Prostate Cancer, Urinary Incontinence, Surgery
Interventions: Augmented Bladder Neck Reconstruction, Standard Bladder Neck Reconstruction; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Incontinence, Urinary Stress, Prostate Cancer, Benign Prostate Hyperplasia
Interventions: Text message reminders; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Male only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Prostate Cancer, Prostatic Neoplasms
Interventions: Docetaxel, Imatinib Mesylate; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 3
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Whole Food Plant-based Diet; Other
Lead sponsor: Pacific Cancer Care; Other
Eligibility: 45 Years to 99 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Monterey, California

Conditions: Prostate Cancer
Interventions: Samarium-153, Total Androgen Suppression (TAS) with Bicalutamide, Total androgen suppression (TAS) with Goserelin Acetate, Radiation Therapy; Drug · Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions: Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration, Magnetic Resonance Imaging; Drug · Procedure · Radiation + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • Albert Lea, Minnesota • Mankato, Minnesota + 3 more

Conditions: Cancer of the Prostate
Interventions: ExoDx Prostate (IntelliScore); Diagnostic Test
Lead sponsor: Exosome Diagnostics, Inc.; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Interventions: saracatinib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Duarte, California

Conditions: Prostate Cancer Surgery, Prostate Cancer Metastatic Disease
Interventions: 0.03mg/kg ZOPOCIANINE given day of surgery, 0.06mg/kg ZOPOCIANINE given day of surgery, 0.03mg/kg ZOPOCIANINE given day prior to surgery, 0.06mg/kg ZOPOCIANINE given days prior to surgery; Drug
Lead sponsor: Clinton Bahler; Other
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Enzalutamide during Lead-in Period, Lead-in Enzalutamide followed by Radium-223/Enzalutamide, Lead-in Enzalutamide followed by Placebo/Enzalutamide, Darolutamide during Lead-in Period, Lead-in Darolutamide followed by Radium-223/Darolutamide, Lead-in Darolutamide followed by Placebo/Darolutamide; Drug
Lead sponsor: MANA RBM; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Myrtle Beach, South Carolina

Conditions: Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions: Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy; Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 229
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 188 more

Conditions: Prostate Carcinoma
Interventions: Best Practice, Discussion, Survey Administration, Virtual Reality; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer

Genetic Biomarker Discovery for Metastatic Prostate Cancer

Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk

Building Community Living Labs in Black Communities to Advance Prostate Health Equity and Reduce Prostate Cancer Disparities in Black Men

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Augmented BLAdder NecK rEconstruction Trial for Improved Urinary Function After Radical Prostatectomy

Effect of Text Message Reminders on M-ISI Score After Prostate Surgery

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Whole Food Plant-based Diet to Improve Outcomes in Prostate Cancer

Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Decision Impact Trial of the ExoDx Prostate (IntelliScore)

AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men